Share Issue/Capital Change • Nov 30, 2023
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
30 November 2023 07:30:00 CET

During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 34,984 series C shares into a total of 34,984 ordinary shares for delivery of shares to participants in the performance-based share saving program that was adopted by the annual general meeting held on 6 May 2020 (LTI 2020).
As of 30 November 2023, the number of shares in Ascelia Pharma AB amounts to 34,871,177 shares, of which 33,757,746 are ordinary shares with one vote each and 1,113,431 are series C shares with 1/10 vote each. The total number of votes in the company amounts to 33,869,089.10.
Contacts
Magnus Corfitzen, CEO Email: [email protected] Tel: +46 735 179 118
Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial) Email: [email protected] Tel: +46 735 179 116
This information was submitted for publication, through the agency of the contact persons set out above.
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-11-30 07:30 CET.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.